Rhizen Pharmaceuticals SA
- Health
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces presentation of interim data from its Tenalisib + Romidepsin combination study in patients…
Read More »